Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MYOC | Q99972 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17104295 | 0.88 | SMN1; SMN2 (0.69) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL1720684 | 0.80 | LMNA (0.81) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL4276324 | 0.78 | TAAR1 (0.64) | LMNAHTTALDH1A1CYP1A2KMT2A | |
| SCHEMBL2180295 | 0.78 | GRM5 (0.71) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL17104325 | 0.76 | ALDH1A1 (0.57) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL4475032 | 0.76 | SMN1; SMN2 (0.60) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL8104824 | 0.75 | MEN1 (0.85) | LMNAHTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4478258 | 0.75 | MEN1 (0.56) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL4477204 | 0.74 | LMNA (0.73) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL4477206 | 0.73 | ALDH1A1 (1.00) | LMNAHTTSMN1; SMN2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1615878-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| EP-1615878-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | LMNA 210/4885HTT 2783/4885SMN1; SMN2 658/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | LMNA 187/4885HTT 3069/4885SMN1; SMN2 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.